The lack of association between components of metabolic syndrome and treatment resistance in depression

Psychopharmacology

Volumn 230, Issue 1, 2013, Pages 15-21

  Sagud, Marina ^a   Mihaljevic Peles, Alma ^a   Uzun, Suzana ^b   Cusa, Bjanka Vuksan ^c   Kozumplik, Oliver ^b   Kudlek Mikulic, Suzan ^c   Mustapic, Maja ^d   Barisic, Ivan ^c   Muck Seler, Dorotea ^d   Pivac, Nela ^d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Psychiatric Hospital Vrap e   (Croatia)

^c KBC Zagreb   (Croatia)

^d RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cardiovascular risk factors; Components of the metabolic syndrome; Major depressive disorder (MDD); Metabolic syndrome (MetS); Treatment resistant depression (TRD)

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MAPROTILINE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLIC SYNDROME X; NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III CRITERIA; PREVALENCE; PRIORITY JOURNAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUICIDE ATTEMPT; TREATMENT RESISTANT DEPRESSION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUICIDE, ATTEMPTED; TIME FACTORS;

EID: 84886260022     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3085-x     Document Type: Article

References (36)

1. Amital D, Fostick L, Silberman A, Beckman M, Spivak B (2008) Serious life events among resistant and non-resistant MDD patients. J Affect Disord 110:260-264
2. Amital D, Fostick L, Silberman A, Calati R, Spindelegger C, Serretti A, Juven-Wetzler A, Souery D, Mendlewicz J, Montgomery S, Kasper S, Zohar J (2012) Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2012.09.002
3. APA, American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edn. American Psychiatric Association, Washington, DC
4. Baeken C, De Raedt R, Bossuyt A (2012) Is treatment-resistance in unipolar melancholic depression characterized by decreased serotonin-2A receptors in the dorsal prefrontal-anterior cingulate cortex? Neuropharmacol 62:340-346
5. Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M (2008) Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiat 9:190-197
6. Carney RM, Freedland KE (2009) Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiat 166:410-417
7. Chokka P, Tancer M, Vikram K, Yeragani VK (2006) Metabolic syndrome: relevance to antidepressant treatment. J Psychiatry Neurosci 31:414
8. Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175-191
9. Daniel WW (1990) Applied nonparametric statistics, 2nd edn. PWS Kent Publishing Company, Boston, MA
10. Gibson TB, Jing Y, Smith Carls G, Kim E, Bagalman JE, Burton WN, Tran QV, Pikalov A, Goetzel RZ (2010) Cost burden of treatment resistance in patients with depression. Am J Manag Care 16:370-377
11. Guo WB, Liu F, Chen JD, Gao K, Xue ZM, Xu XJ, Wu RR, Tan CL, Sun XL, Liu ZN, Chen HF, Zhao JP (2012) Abnormal neural activity of brain regions in treatment-resistant and treatment-sensitive major depressive disorder: a resting-state fMRI study. J Psychiatr Res 46:1366-1373
12. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
13. Hoogenboom WS, Perlis RH, Smoller JW, Zeng-Treitler Q, Gainer VS, Murphy SN, Churchill SE, Kohane IS, Shenton ME, Iosifescu DV (2012) Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: a diffusion tensor imaging study using legacy data. World J Biol Psychiat. doi: 10.3109/15622975.2012.669499
14. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M (2005) Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 67:703-706
15. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M (2008) Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiat 69:178-182
16. Little A (2009) Treatment-resistant depression. Am Fam Physician 80:167-172
17. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M (2008) MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32:1439-1444
18. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB (2006) The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J Clin Endocrinol Metab 91:718-721
19. Muldoon MF, Mackey RH, Sutton-Tyrrell K, Flory JD, Pollock BG, Manuck SB (2007) Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosis. Stroke 38:2228-2233
20. Muck-Seler D, Sagud M, Mihaljevi-Peles A, Jakovljevi M, Pivac N (2011) Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women. J Clin Psychopharmacol 31:387-390
21. National Cholesterol Education Program (US). Expert panel on detection evaluation and treatment of high blood cholesterol in adults. (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III): final report. The Program, Washington, D.C
22. Nemeroff CB (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiat 68(Suppl 8):17-25
23. Olin B, Jayewardene AK, Bunker M, Moreno F (2012) Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. PLoS One 7:e48002. doi: 10.1371/journal.pone.0048002
24. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L (2012) rTMS age-dependent response in treatment-resistant depressed subjects: a mini-review. CNS Spectr 17:24-30
25. Pannier B, Thomas F, Eschwege E, Bean K, Benetos A, Leocmach Y, Danchin N, Guize L (2006) Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the «SYMFONIE» study. Diabetes Metab 32:467-474
26. Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA (2003) Serum cholesterol in treatment-resistant depression. Neuropsychobiology 47:146-151
27. Phillips JL, Batten LA, Aldosary F, Tremblay P, Blier P (2012) Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression. J Clin Psychiat 73:625-631
28. Raikkonen K, Matthews KA, Kuller LH (2007) Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of world health organization, adult treatment panel III, and international diabetes foundation definitions. Diabetes Care 30:2761-2761
29. Richter N, Juckel G, Assion HJ (2010) Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci 260:41-49
30. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S (2012) European Group for the Study of Resistant Depression (GSRD) - Where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2012.02.006
31. Shah PJ, Glabus MF, Goodwin GM, Ebmeier KP (2002) Chronic, treatment-resistant depression and right fronto-striatal atrophy. Brit J Psychiat 180:434-440
32. Skilton MR, Moulin P, Terra JL, Bonnet F (2007) Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiat 62:1251-1257
33. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J (1999) Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharm 9:83-91
34. Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiat 68:1062-1070
35. Toker S, Shirom A, Melamed S (2008) Depression and the metabolic syndrome: gender-dependent associations. Depression and Anxiety 25:661-669
36. Zeugmann S, Quante A, Heuser I, Schwarzer R, Anghelescu I (2010) Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome. J Clin Psychiat 71:1007-1016